News — DRACO drug RSS

RIDER Institute Q&A

DRACO Q&A – the following Questions (Q:) were asked by several of you who completed the provided form. All answers following the “A:” were written by Dr.Rider. Q: Judging by the slow pace of FDA drug approval, is there a way to get a more blanket-like approval for concurrent trials of the DRACO method for different diseases? A: That is a very interesting idea, but before we can get to questions about FDA approval, we need to test and optimize DRACOs against major clinically relevant viruses in cells and in animal experiments. Q: First of all, thanks for your passion and hard work to help make the world a better place to live. I would like to know if DRACOs can address infections of...

Continue reading

We're LIVE on IndieGoGo raising funds for DRACO Research

The RIDER Institute announces an IndieGoGo crowdfunding campaign to help fund Dr. Todd Rider's research and development of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against all 18 viruses tested in previous proof-of-concept experiments. In the campaign that starts on May 3, 2016 at runs for 60 days, we are raising new funding to test and optimize DRACOs against major clinical viruses in cells. If this work is successful, it should lead to preclinical animal trials and ultimately hopefully to human clinical trials. Dr. Todd Rider invented DRACO (Double-stranded RNA Activated Caspase Oligomerizer) broad-spectrum antiviral therapeutics at MIT and published proof-of-concept experiments in the peer-reviewed journal PLoS ONE ( In human and animal cells, DRACOs have been effective...

Continue reading

Testing and Optimizing DRACO Therapeutics Against Members of the Herpesvirus Family

April 12, 2016 BACKGROUND AND MOTIVATION Currently there are relatively few prophylactics or therapeutics for viruses, and most that do exist are highly pathogen-specific or have undesirable side effects or other disadvantages. We have developed a radically new, broad-spectrum antiviral therapeutic/prophylactic that has the potential to revolutionize the treatment of viral infections. Our Double-stranded RNA Activated Caspase Oligomerizer (DRACO) approach selectively induces apoptosis (cell suicide) in cells containing viral double-stranded RNA (dsRNA). DRACO should recognize virus-infected cells and rapidly kill those cells without harming uninfected cells, thereby terminating the viral infection while minimizing the impact on the host (PLoS ONE 6:e22572, 2011; Nature Biotechnology 29:885, 2011; U.S. patents 7,125,839, 7,566,694, and others pending). We have previously created an initial version...

Continue reading